ALBANY MOLECULAR RESEARCH INC Insider Trading for February 2017
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ALBANY MOLECULAR RESEARCH INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in ALBANY MOLECULAR RESEARCH INC for February 2017.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 21 2017 | AMRI | ALBANY MOLECULAR R ... | Ladin Felicia I | SVP, Treasurer & CF ... | Payment of Exercise | F | 18.71 | 2,097 | 39,235 | 58,936 | 61 K to 58.9 K (-3.44 %) |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | HENDERSON LORI M. | SVP, Secretary & Ge ... | Option Exercise | A | 18.41 | 44,251 | 814,661 | 44,251 | |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | HENDERSON LORI M. | SVP, Secretary & Ge ... | Grant | A | 0.00 | 6,747 | 0 | 62,427 | 55.7 K to 62.4 K (+12.12 %) |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | HENDERSON LORI M. | SVP, Secretary & Ge ... | Grant | A | 0.00 | 8,990 | 0 | 55,680 | 46.7 K to 55.7 K (+19.25 %) |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | RYAN UNA S | Director | Option Exercise | A | 18.41 | 9,358 | 172,281 | 9,358 | |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | RYAN UNA S | Director | Grant | A | 0.00 | 3,802 | 0 | 46,845 | 43 K to 46.8 K (+8.83 %) |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | ROTH ARTHUR J | Director | Option Exercise | A | 18.41 | 9,358 | 172,281 | 9,358 | |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | ROTH ARTHUR J | Director | Grant | A | 0.00 | 3,802 | 0 | 47,575 | 43.8 K to 47.6 K (+8.69 %) |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | NAPOLITANO FERNANDO | Director | Option Exercise | A | 18.41 | 9,358 | 172,281 | 9,358 | |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | NAPOLITANO FERNANDO | Director | Grant | A | 0.00 | 3,802 | 0 | 3,802 | 0 to 3.8 K |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | OCONNOR KEVIN | Director | Option Exercise | A | 18.41 | 9,358 | 172,281 | 9,358 | |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | OCONNOR KEVIN | Director | Grant | A | 0.00 | 3,802 | 0 | 53,275 | 49.5 K to 53.3 K (+7.68 %) |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | Deming David H | Director | Option Exercise | A | 18.41 | 9,358 | 172,281 | 9,358 | |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | Deming David H | Director | Grant | A | 0.00 | 3,802 | 0 | 6,838 | 3 K to 6.8 K (+125.23 %) |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | HAGEN KENNETH PAUL | Director | Option Exercise | A | 18.41 | 9,358 | 172,281 | 9,358 | |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | HAGEN KENNETH PAUL | Director | Grant | A | 0.00 | 3,802 | 0 | 6,838 | 3 K to 6.8 K (+125.23 %) |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | D AMBRA THOMAS E | Director | Option Exercise | A | 18.41 | 9,358 | 172,281 | 9,358 | |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | D AMBRA THOMAS E | Director | Grant | A | 0.00 | 3,802 | 0 | 2,478,089 | 2.5 M to 2.5 M (+0.15 %) |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | FINE MARGALIT | Executive Vice Pres ... | Option Exercise | A | 18.41 | 21,725 | 399,957 | 21,725 | |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | FINE MARGALIT | Executive Vice Pres ... | Grant | A | 0.00 | 3,312 | 0 | 7,725 | 4.4 K to 7.7 K (+75.05 %) |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | FINE MARGALIT | Executive Vice Pres ... | Grant | A | 0.00 | 4,413 | 0 | 4,413 | 0 to 4.4 K |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | Marth William S | President and CEO | Option Exercise | A | 18.41 | 133,690 | 2,461,233 | 133,690 | |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | Marth William S | President and CEO | Grant | A | 0.00 | 20,383 | 0 | 521,004 | 500.6 K to 521 K (+4.07 %) |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | Marth William S | President and CEO | Grant | A | 0.00 | 27,159 | 0 | 500,621 | 473.5 K to 500.6 K (+5.74 %) |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | MADDALUNA ANTHONY J | Director | Option Exercise | A | 18.41 | 9,358 | 172,281 | 9,358 | |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | MADDALUNA ANTHONY J | Director | Grant | A | 0.00 | 3,802 | 0 | 11,210 | 7.4 K to 11.2 K (+51.32 %) |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | CONWAY CHRISTOPHER M. | SVP, Discovery and ... | Option Exercise | A | 18.41 | 21,056 | 387,641 | 21,056 | |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | CONWAY CHRISTOPHER M. | SVP, Discovery and ... | Grant | A | 0.00 | 3,210 | 0 | 45,501 | 42.3 K to 45.5 K (+7.59 %) |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | CONWAY CHRISTOPHER M. | SVP, Discovery and ... | Grant | A | 0.00 | 4,278 | 0 | 42,291 | 38 K to 42.3 K (+11.25 %) |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | Ladin Felicia I | SVP, Treasurer & CF ... | Option Exercise | A | 18.41 | 46,791 | 861,422 | 46,791 | |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | Ladin Felicia I | SVP, Treasurer & CF ... | Grant | A | 0.00 | 7,134 | 0 | 61,033 | 53.9 K to 61 K (+13.24 %) |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | Ladin Felicia I | SVP, Treasurer & CF ... | Grant | A | 0.00 | 9,506 | 0 | 53,899 | 44.4 K to 53.9 K (+21.41 %) |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | Svokos George | Chief Operating Off ... | Option Exercise | A | 18.41 | 56,818 | 1,046,019 | 56,818 | |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | Svokos George | Chief Operating Off ... | Grant | A | 0.00 | 8,663 | 0 | 122,123 | 113.5 K to 122.1 K (+7.64 %) |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | Svokos George | Chief Operating Off ... | Grant | A | 0.00 | 11,543 | 0 | 113,460 | 101.9 K to 113.5 K (+11.33 %) |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | Gutierrez Fuentes Luis Gerardo | Director | Option Exercise | A | 18.41 | 9,358 | 172,281 | 9,358 | |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | Gutierrez Fuentes Luis Gerardo | Director | Grant | A | 0.00 | 3,802 | 0 | 6,656 | 2.9 K to 6.7 K (+133.22 %) |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | BOYER MILTON | SVP, Drug Product M ... | Option Exercise | A | 18.41 | 29,980 | 551,932 | 29,980 | |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | BOYER MILTON | SVP, Drug Product M ... | Grant | A | 0.00 | 4,571 | 0 | 39,763 | 35.2 K to 39.8 K (+12.99 %) |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | BOYER MILTON | SVP, Drug Product M ... | Grant | A | 0.00 | 6,090 | 0 | 35,192 | 29.1 K to 35.2 K (+20.93 %) |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | Hagen Steven R | SVP Manufacturing & ... | Option Exercise | A | 18.41 | 29,412 | 541,475 | 29,412 | |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | Hagen Steven R | SVP Manufacturing & ... | Grant | A | 0.00 | 4,484 | 0 | 40,867 | 36.4 K to 40.9 K (+12.32 %) |
| Feb 10 2017 | AMRI | ALBANY MOLECULAR R ... | Hagen Steven R | SVP Manufacturing & ... | Grant | A | 0.00 | 5,975 | 0 | 36,383 | 30.4 K to 36.4 K (+19.65 %) |
| Feb 07 2017 | AMRI | ALBANY MOLECULAR R ... | HENDERSON LORI M. | SVP, Secretary & Ge ... | Payment of Exercise | F | 18.52 | 504 | 9,334 | 46,690 | 47.2 K to 46.7 K (-1.07 %) |
| Feb 07 2017 | AMRI | ALBANY MOLECULAR R ... | HENDERSON LORI M. | SVP, Secretary & Ge ... | Payment of Exercise | F | 18.52 | 674 | 12,482 | 47,194 | 47.9 K to 47.2 K (-1.41 %) |
| Feb 07 2017 | AMRI | ALBANY MOLECULAR R ... | HENDERSON LORI M. | SVP, Secretary & Ge ... | Payment of Exercise | F | 18.52 | 2,363 | 43,763 | 47,868 | 50.2 K to 47.9 K (-4.70 %) |
| Feb 07 2017 | AMRI | ALBANY MOLECULAR R ... | CONWAY CHRISTOPHER M. | SVP, Discovery and ... | Payment of Exercise | F | 18.52 | 491 | 9,093 | 38,013 | 38.5 K to 38 K (-1.28 %) |
| Feb 07 2017 | AMRI | ALBANY MOLECULAR R ... | CONWAY CHRISTOPHER M. | SVP, Discovery and ... | Payment of Exercise | F | 18.52 | 553 | 10,242 | 38,504 | 39.1 K to 38.5 K (-1.42 %) |
| Feb 07 2017 | AMRI | ALBANY MOLECULAR R ... | CONWAY CHRISTOPHER M. | SVP, Discovery and ... | Payment of Exercise | F | 18.52 | 1,900 | 35,188 | 39,057 | 41 K to 39.1 K (-4.64 %) |
| Feb 07 2017 | AMRI | ALBANY MOLECULAR R ... | Hagen Steven R | SVP Manufacturing & ... | Payment of Exercise | F | 18.52 | 488 | 9,038 | 30,408 | 30.9 K to 30.4 K (-1.58 %) |
| Feb 07 2017 | AMRI | ALBANY MOLECULAR R ... | Hagen Steven R | SVP Manufacturing & ... | Payment of Exercise | F | 18.52 | 664 | 12,297 | 30,896 | 31.6 K to 30.9 K (-2.10 %) |
| Feb 07 2017 | AMRI | ALBANY MOLECULAR R ... | Hagen Steven R | SVP Manufacturing & ... | Payment of Exercise | F | 18.52 | 2,291 | 42,429 | 31,560 | 33.9 K to 31.6 K (-6.77 %) |
| Feb 07 2017 | AMRI | ALBANY MOLECULAR R ... | D AMBRA THOMAS E | Director | Payment of Exercise | F | 18.52 | 1,034 | 19,150 | 2,474,287 | 2.5 M to 2.5 M (-0.04 %) |
| Feb 07 2017 | AMRI | ALBANY MOLECULAR R ... | Svokos George | Chief Operating Off ... | Payment of Exercise | F | 18.52 | 751 | 13,909 | 101,917 | 102.7 K to 101.9 K (-0.73 %) |
| Feb 07 2017 | AMRI | ALBANY MOLECULAR R ... | Svokos George | Chief Operating Off ... | Payment of Exercise | F | 18.52 | 596 | 11,038 | 102,668 | 103.3 K to 102.7 K (-0.58 %) |
| Feb 07 2017 | AMRI | ALBANY MOLECULAR R ... | Svokos George | Chief Operating Off ... | Payment of Exercise | F | 18.52 | 2,381 | 44,096 | 103,264 | 105.6 K to 103.3 K (-2.25 %) |
| Feb 07 2017 | AMRI | ALBANY MOLECULAR R ... | Ladin Felicia I | SVP, Treasurer & CF ... | Payment of Exercise | F | 18.52 | 655 | 12,131 | 44,393 | 45 K to 44.4 K (-1.45 %) |
| Feb 07 2017 | AMRI | ALBANY MOLECULAR R ... | BOYER MILTON | SVP, Drug Product M ... | Payment of Exercise | F | 18.52 | 339 | 6,278 | 29,102 | 29.4 K to 29.1 K (-1.15 %) |
| Feb 07 2017 | AMRI | ALBANY MOLECULAR R ... | Marth William S | President and CEO | Payment of Exercise | F | 18.52 | 1,942 | 35,966 | 473,462 | 475.4 K to 473.5 K (-0.41 %) |
| Feb 07 2017 | AMRI | ALBANY MOLECULAR R ... | Marth William S | President and CEO | Payment of Exercise | F | 18.52 | 41,626 | 770,914 | 475,404 | 517 K to 475.4 K (-8.05 %) |
| Feb 01 2017 | AMRI | ALBANY MOLECULAR R ... | Hagen Steven R | SVP Manufacturing & ... | Payment of Exercise | F | 18.11 | 531 | 9,616 | 33,851 | 34.4 K to 33.9 K (-1.54 %) |
| Feb 01 2017 | AMRI | ALBANY MOLECULAR R ... | Hagen Steven R | SVP Manufacturing & ... | Payment of Exercise | F | 18.11 | 531 | 9,616 | 34,382 | 34.9 K to 34.4 K (-1.52 %) |
| Feb 01 2017 | AMRI | ALBANY MOLECULAR R ... | D AMBRA THOMAS E | Director | Payment of Exercise | F | 18.11 | 2,825 | 51,161 | 2,475,321 | 2.5 M to 2.5 M (-0.11 %) |
| Feb 01 2017 | AMRI | ALBANY MOLECULAR R ... | HENDERSON LORI M. | SVP, Secretary & Ge ... | Payment of Exercise | F | 18.11 | 553 | 10,015 | 50,231 | 50.8 K to 50.2 K (-1.09 %) |
| Feb 01 2017 | AMRI | ALBANY MOLECULAR R ... | HENDERSON LORI M. | SVP, Secretary & Ge ... | Payment of Exercise | F | 18.11 | 553 | 10,015 | 50,784 | 51.3 K to 50.8 K (-1.08 %) |
| Feb 01 2017 | AMRI | ALBANY MOLECULAR R ... | CONWAY CHRISTOPHER M. | SVP, Discovery and ... | Payment of Exercise | F | 18.11 | 1,061 | 19,215 | 40,957 | 42 K to 41 K (-2.53 %) |